0,99 €
inkl. MwSt.
Sofort per Download lieferbar
payback
0 °P sammeln
  • Format: ePub

Cardioembolic strokes account for one third of ischemic strokes and atrial fibrillation (AF) representing the main source of this stroke subtype. The rate of stroke is 5%/year in patients with AF. Patients with AF have a 2-7 fold increased risk of stroke compared to patients without. Stroke prevention in atrial fibrillation (SPAF) is therefore of utmost importance and represents a major point in the modern management of AF. This booklet provides an overview of new oral anticoagulants used, listing their pharmacokinetis profile, the evidence of efficacy and their clinical use.

Produktbeschreibung
Cardioembolic strokes account for one third of ischemic strokes and atrial fibrillation (AF) representing the main source of this stroke subtype. The rate of stroke is 5%/year in patients with AF. Patients with AF have a 2-7 fold increased risk of stroke compared to patients without. Stroke prevention in atrial fibrillation (SPAF) is therefore of utmost importance and represents a major point in the modern management of AF. This booklet provides an overview of new oral anticoagulants used, listing their pharmacokinetis profile, the evidence of efficacy and their clinical use.